Navigation Links
Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO)
Date:9/26/2007

e scientific information discussed in this news release related to our product candidate is preliminary and investigative. The product candidate is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidate. Only the FDA can determine whether the product candidate is safe and effective for the use(s) being investigated. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on August 7, 2007 and is available from the SEC's website (http://www.sec.gov) and on our website (http://www.thresholdpharm.com) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.

Contact:

Denise T. Powell

Sr. Director, Corporate Communications

Threshold Pharmaceuticals, Inc.

650-474-8206

dpowell@thresholdpharm.com


'/>"/>
SOURCE Threshold Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  BC Technical, the largest nationwide, ... America , Inc., a leading provider of Siemens Nuclear ... long-term agreement naming BC Technical as the authorized provider ... MiE and BC Technical announced today that the ... BC Technical as the service and systems provider for ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
(Date:7/10/2014)... , July 10, 2014 Decision Resources ... awareness of the U.S. Food and Drug Administration,s (FDA) ... phosphate binder Velphoro, which was approved by the FDA ... chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 : ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... STEVENSVILLE, Md., July 13, 2011 Vapotherm, a privately held ... announced today that it has received approval from the Medical ... device which will be launched later this year in the ... Flow Specialty Gas Program. "We are pleased ...
... 2011 The U.S. Food and Drug Administration today ... and patients that surgical placement of mesh through the ... to greater risk than other surgical options. ... communication also says that with the exposure to greater ...
Cached Medicine Technology:Vapotherm Announces Approval in Canada for New High Flow Device Designed for Heliox 2FDA: Surgical Placement of Mesh to Repair Pelvic Organ Prolapse Poses Risks 2FDA: Surgical Placement of Mesh to Repair Pelvic Organ Prolapse Poses Risks 3FDA: Surgical Placement of Mesh to Repair Pelvic Organ Prolapse Poses Risks 4
(Date:7/12/2014)... Response Management Systems is a crucial peak load management ... energy supply and demand. With the help of DRMS, ... increasing pressure on the grid) and replaced by Advanced ... and thermostats for load reduction. , DRMS is ... government mandates and benefits for energy efficiency and conservation ...
(Date:7/12/2014)... (HealthDay News) -- If you make exercise fun, you,ll eat ... experiment, 56 adults were led on a 1.4-mile walk and ... a scenic walk. The participants were given lunch after the ... outing ate 35 percent more chocolate pudding for dessert than ... In another experiment, 46 adults were given mid-afternoon snacks after ...
(Date:7/12/2014)... Using and carrying around a catheter bag ... Ashland, Va., decided that there needed to be an ... conceive of our design," he said. , They then ... provides an inconspicuous way to use and carry a ... promotes comfort and peace of mind. Producible in design ...
(Date:7/12/2014)... “Critical Care Therapeutics in Major ... Four-Factor PCCs and Recombinant Products to Drive Market,” ... market in the US, UK, France, Germany, Italy, ... estimation of market size for 2013, along with ... indications that are being treated using the five ...
(Date:7/12/2014)... A recent article released by Seattle's well known ... for those seeking cosmetic surgical procedures in summer months ... the heat begins to enliven the rainy Pacific Northwest, many ... that they didn’t work out as much during the winter ... sudden surge of people eager to look their best for ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2
... enhance bilateral cooperation between India and Fiji Islands in ... the Union Cabinet today.// ,The Cabinet meeting ... facto approval for signing of the agreement between the ... and Broadcasting Minister Priyaranjan Dasmunsi told reporters here. , ...
... regulation of infertility clinics has been highlighted again by ... to Senator Mary Henry.// ,Eight years ago ... private members bill to regulate such clinics. Recently, Health ... for the regulation of assisted human reproduction in Ireland. ...
... and boys with autism suffer from poor social and communication ... their amygdala, according to the findings// of a new study. ... University of California, Davis conducted a survey on the number ... 10 nonautistic males ranging from ages 10 to 44. Their ...
... 18 people, mostly children and women, have died of ... Dhemaji since the beginning of the month. // ... of the disease in Lakhimpur district, where nearly 100 ... four children died of the disease even as the ...
... court in the US has ruled against the company in ... // ,The company informed the Bombay Stock Exchange ... Virginia has issued an opinion following the completion of a ... Altace (Ramipril) drug and found the patent to be valid., ...
... Access to necessary dental health services and treatment is just ... and weight, for maintaining// good health. ,It has ... spent on health over the past 12 months. ... billions of dollars, certain individuals as well as groups of ...
Cached Medicine News:Health News:Regulation of Infertility Clinics Needed 2Health News:Dental Health, a Much Overlooked Subject 2
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
10 L, Bulk Recommended for 5 and 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates....
This extended 10 L tip additionally combats contamination by keeping your pipettor out of 1.5 L and 2.0 L tubes....
1000 L, Bulk Recommended for 500 and 1000 L pipettes....
Medicine Products: